|
| Status |
Public on Oct 07, 2009 |
| Title |
LOX1 oxLDL 12hr 282295823 |
| Sample type |
RNA |
| |
|
| Source name |
LOX1_oxLDL_12hr
|
| Organism |
Homo sapiens |
| Characteristics |
Extract:LOX-1:221403
Extract Description:LOX1_oxLDL_12hr:221403
Quality: Classification:Good
Quality: Gradient Severity:0.03
Quality: Distortion Severity:0.01
Quality: Defective Area (%):0
Quality: Outlier Area (%):0.01
Quality: 3'/5' Mean:1.62
Quality: Background Mean Dev.:0.18
Quality: Absent (%):58.56
Quality: Absent (%) Dev.:0.24
Quality: Scaling Factor:0.68
Quality: Scaling Factor Dev.:0.56
Pretreatment [C]:LOX1
Time point [C]:12 hours
Treatment [C]:Oxidized LDL
Genomic ID [C]:221403
Cell name [C]:HAECT
Treatment amount [C]:50 ug/ml
Cell type [C]:Endothelial
Organism species [C]:Human:Homo sapiens
Cohort name [C]:LOX1_oxLDL_12hr
RNA extraction source key [A]:282295823
|
| Extracted molecule |
polyA RNA |
| Extraction protocol |
RNA was extracted from HAECT cells
|
| Label |
biotin
|
| Label protocol |
Affymetrix in-vitro labeling protocol
|
| |
|
| Hybridization protocol |
Affymetrix standard hybridization protocol
|
| Scan protocol |
Affymetrix standard scan protocol
|
| Description |
LOX1_oxLDL_12hr:221403
|
| Data processing |
Affymetrix MAS 5.0 algorithm
|
| |
|
| Submission date |
Oct 09, 2008 |
| Last update date |
Oct 07, 2009 |
| Contact name |
Andrew Hill |
| E-mail(s) |
andrew.hill@pfizer.com
|
| Phone |
617-674-6341
|
| Organization name |
Pfizer
|
| Department |
Research Business Technology
|
| Street address |
300 Technology Square
|
| City |
Cambridge |
| State/province |
MA |
| ZIP/Postal code |
02139 |
| Country |
USA |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE13139 |
LOX-1-dependent transcriptional regulation after oxidized LDL (OxLDL) treatment of human aortic endothelial cells. |
|
